Although preclinical work in rodents supports a role for both CB1 and CB2, through the use of both receptor-selective (Deng et al., 2012; Vera et al., 2013) and/or mixed CB1/CB2 agonists (Vera et al., 2013; Nealon et al., 2019; Henderson-Redmond et al., 2020) in mediating cisplatin-induced neuropathy, results of clinical work are slightly less clear. This evidence concerns the gene CNR1 and neuropathy.